Feasibility of Patient-Derived 3D Gastrointestinal Stromal Tumour Models as Alternatives for In Vivo Mouse Models
Dina Mönch(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), J. Koch(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Annika Maaß(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Philipp Renner(Robert Bosch Hospital), Annette M. Staiger(Robert Bosch Hospital), Christian Schmees(Technical University of Munich), Thomas E. Mürdter(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Marc‐H. Dahlke(Robert Bosch Hospital), Matthias Schwab(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Anna Binner(Natural and Medical Sciences Institute), Tobias Leibold(Robert Bosch Hospital), Julia Thiel(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Meng Dong(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Katrin S. Kurz(Robert Bosch Hospital), G. Ott(Robert Bosch Hospital), E Wegner(Natural and Medical Sciences Institute)
Cited by 1
Related Papers
A roadmap for graphene
|Nature|2012|9.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
|The Lancet Oncology|2015|613
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566